I'm a postdoctoral researcher in a molecular oncology lab, and our team is trying to stay current with the rapid pace of CRISPR gene editing breakthroughs, especially those with therapeutic potential. We're particularly interested in recent advances like prime editing and base editing for correcting point mutations in vivo. The literature is expanding so quickly that it's difficult to separate truly transformative preclinical studies from incremental improvements. For those closely following the translational side, which recent papers or clinical trial announcements from the last 12-18 months do you consider the most significant leap forward? I'm especially keen on understanding which delivery systems (like lipid nanoparticles or viral vectors) are showing the most promise for targeting specific tissues like the liver or central nervous system in animal models.
The standout leap right now is Intellia's NTLA-2001 program for transthyretin amyloidosis, which uses lipid nanoparticle–delivered CRISPR-Cas9 to edit the liver. Early clinical results showed meaningful knockdown of the target protein with a favorable safety profile in small cohorts, marking a real in-human demonstration of in vivo genome editing. It’s still early days, but it’s the closest thing we have to a therapeutic CRISPR in humans for a systemic disease.
On the preclinical/ translational front, base editing and prime editing advances are trending toward in vivo demonstrations, often in mice. Expect more papers showing tissue-specific delivery and improved specificity using lipid nanoparticles for liver and refined viral vectors or nanoparticles for CNS. The big question remains delivering sufficient payload with low immunogenicity and precise on-target edits in complex tissues.
Delivery systems matter a lot for target tissue. Liver work has benefited greatly from lipid nanoparticles and GalNAc-conjugated strategies that favor hepatocytes, while CNS targets have relied more on AAV vectors with tropism for brain routes or specialized LNPs designed to cross the blood–brain barrier. Each platform has trade-offs in efficiency, payload size, and safety that shape which approach a given oncogene or disease model can tolerate.
If you’d like, I can pull together a compact, up-to-date reading list (papers + the status of clinical trials) specifically for liver vs CNS delivery in the last 12–18 months. Sharing your disease context or model system would let me tailor the picks to meaningful translational relevance.
Would you prefer a focused digest (6–8 papers with a one-paragraph takeaway for each) or a longer set of 12–15 papers plus trial summaries? I can also include some quick takeaways on study design and common limitations to watch for when evaluating translational potential.